Medical Developments International (ASX:MVP) launches Penthrox in Italy

Company News

by Rachael Jones

Medical Developments International (ASX:MVP) is delighted to announce that Penthrox has been launched in Italy.

Penthrox is an inhaled medication primarily used to reduce pain following trauma.

A medical trial in Italy with a study of 272 trauma patients in 15 Italian emergency units showed that Penthrox was superior to Standard of Care, including Opioids, for adult trauma pain patients.

MVP CEO John Sharman says “The launch of Penthrox in Italy will trigger another milestone payment from our partner Mundipharma of US$2million which is expected during 2020".

Shares in Medical Developments International (ASX:MVP) are trading 3.1 per cent higher at $5.97.

Rachael Jones

Finance News Network
Rachael comes to FNN after working for Fairfax Media covering international breaking news, including the global economy and politics. She joined FNN in February 2018. She has reported on Australia’s finance news for various organisations since 2000 and has also interviewed a number of key business players, including Bill Gates. Rachael has also worked across a number of countries, including the UK and the US.